These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 27824816)
21. Genetic therapies for inherited neuromuscular disorders. Scoto M; Finkel R; Mercuri E; Muntoni F Lancet Child Adolesc Health; 2018 Aug; 2(8):600-609. PubMed ID: 30119719 [TBL] [Abstract][Full Text] [Related]
22. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Guncay A; Yokota T Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833 [No Abstract] [Full Text] [Related]
23. Upcoming market catalysts in Q1 2021. Dilzer K Nat Rev Drug Discov; 2021 Jan; 20(1):9. PubMed ID: 33299128 [No Abstract] [Full Text] [Related]
25. Why dystrophin quantification is key in the eteplirsen saga. Aartsma-Rus A; Arechavala-Gomeza V Nat Rev Neurol; 2018 Aug; 14(8):454-456. PubMed ID: 29967362 [No Abstract] [Full Text] [Related]
26. Year in review 2019: Neuromuscular diseases. Birnkrant DJ; Black JB Pediatr Pulmonol; 2020 Oct; 55(10):2542-2546. PubMed ID: 32691988 [TBL] [Abstract][Full Text] [Related]
27. Muscular Dystrophy Drug Could Pave Way for RNA Medications. Morrow T Manag Care; 2016 Apr; 25(4):30-2. PubMed ID: 27280190 [No Abstract] [Full Text] [Related]
29. Eteplirsen (Exondys 51) for duchenne muscular dystrophy. Med Lett Drugs Ther; 2016 Nov; 58(1507):145-146. PubMed ID: 27805575 [No Abstract] [Full Text] [Related]
30. Life in the Fast Track. Reinke T Manag Care; 2016 Jan; 25(1):16, 21. PubMed ID: 26882624 [No Abstract] [Full Text] [Related]
31. A Phase I/IIa Clinical Trial in Duchenne Muscular Dystrophy Using Systemically Delivered Morpholino Antisense Oligomer to Skip Exon 53 (SKIP-NMD). Hum Gene Ther Clin Dev; 2015 Jun; 26(2):92-5. PubMed ID: 26086759 [No Abstract] [Full Text] [Related]
32. Exon Skipping Therapy. Young CS; Pyle AD Cell; 2016 Nov; 167(5):1144. PubMed ID: 27863231 [TBL] [Abstract][Full Text] [Related]
33. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997. Kulynych J Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555 [No Abstract] [Full Text] [Related]
34. New Treatment for Duchenne Muscular Dystrophy. Aschenbrenner DS Am J Nurs; 2017 Jun; 117(6):22-23. PubMed ID: 28541984 [No Abstract] [Full Text] [Related]
35. The evolution of patient-focused drug development and Duchenne muscular dystrophy. Crossnohere NL; Fischer R; Crossley E; Vroom E; Bridges JF Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):57-68. PubMed ID: 32098551 [No Abstract] [Full Text] [Related]
37. Discussion: The FDA is Unprepared for Personalized Medicine. Tabarrok A Biostatistics; 2017 Jul; 18(3):403-404. PubMed ID: 28633317 [No Abstract] [Full Text] [Related]
39. Post-market drug safety evidence sources: an analysis of FDA drug safety communications. Ishiguro C; Hall M; Neyarapally GA; Dal Pan G Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1134-6. PubMed ID: 23033257 [No Abstract] [Full Text] [Related]
40. New Drugs 2017, part 3. Hussar DA Nursing; 2017 Nov; 47(11):26-32. PubMed ID: 28991071 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]